This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the second quarter. It lifts sales and earnings expectations for the year. Shares rise in pre-market trading
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.
Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen & Novartis' Alzheimer Studies End in Another Failure
by Zacks Equity Research
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
Will Patent Woes Boost Pharma Stock Megamergers Further?
by Nilanjan Banerjee
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
Top Analyst Reports for Boeing, 3M & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), 3M (MMM) and U.S. Bancorp (USB).
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Atara Reports Initial Data for Multiple Sclerosis Candidate
by Zacks Equity Research
Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.
5 ROE Stocks to Buy as Trade Talks Resume Ahead of G20 Summit
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
3 Reasons Why Growth Investors Shouldn't Overlook Biogen (BIIB)
by Zacks Equity Research
Biogen (BIIB) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
Top Stock Reports for Union Pacific, NextEra & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), NextEra (NEE) and Biogen (BIIB).
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
by Zacks Equity Research
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
Biogen (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed the most recent trading day at $230.86, moving +0.19% from the previous trading session.
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed the most recent trading day at $227.33, moving +1.33% from the previous trading session.
Celgene's Filing for Ozanimod Accepted for Review in US/EU
by Zacks Equity Research
The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.
Biogen Reports Interim Phase III Data on Diroximel Fumarate
by Zacks Equity Research
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts
by Zacks Equity Research
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen (BIIB) closed at $223.40, marking a -0.95% move from the previous day.
Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma
by Zacks Equity Research
Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.
Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems
by Zacks Equity Research
Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.
Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)
by Benjamin Rains
Let's look at what investors should expect from some of the more notable tech companies still left to report: Veeva Systems Inc. (VEEV), Workday, Inc. (WDAY), and Palo Alto Networks, Inc. (PANW).